Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
Novo Nordisk’s share price fell over 8% on Wednesday after the company reported lower-than-expected sales of Wegovy.
There were plenty of business losers in 2024, but only one for whom the sky was literally falling. In short: Boeing had a bad year.
Luxury brands were riding the subway instead of lounging in limos this year, though a couple of brands were able to buck the trend.
As the dealmaking environment improved in 2024 thanks to the bull market and interest-rate cuts, investment bankers reaped a windfall.